Developer docs
API playgroundTry for free, no card

Search company profiles

Cadence Neuroscience

Full company profile

uuid0002b6h

Namestring
Cadence Neuroscience
Legal namestring
Cadence Neuroscience, Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Cadence Neuroscience, Inc. is a privately held, clinical-stage medical device company founded in 2017 and headquartered in Redmond, Washington (incubated at Mayo Clinic in Rochester, Minnesota). The company is developing an implantable neuromodulation system called the Cadence Neuromodulation System, also referred to as Biomarker Targeted Stimulation (BTS), for the treatment of drug-resistant focal epilepsy in adults and children. The system combines established neuromodulation hardware with proprietary software that monitors real-time EEG biomarkers and adaptively adjusts stimulation parameters for each patient, distinguishing it from fixed or reactive stimulation approaches such as VNS, RNS, and DBS.

The technology was developed at Mayo Clinic over more than 10 years of clinical use and is exclusively licensed to Cadence. Early clinical data indicates that approximately 50% of patients treated with the therapy achieved seizure freedom, materially exceeding reported outcomes for existing neuromodulation alternatives (VNS ~6%, RNS ~8%, DBS ~12%). Cadence is pursuing regulatory clearance via the FDA Humanitarian Device Exemption pathway and received approval of its Investigational Device Exemption in mid-2026, with a pivotal clinical study planned later that year. The company is supported by strategic and financial partners including Mayo Clinic, Angelini Ventures, F-Prime, JAZZ Venture Partners, Lumira Ventures, Mayo Foundation, and LivaNova, with cumulative funding of approximately $41 million across a $15 million Series A (2019) and a $26 million Series B (2023).

The business model centers on hardware sales of the implantable neuromodulation device to hospitals and specialized epilepsy treatment centers following regulatory approval. Until then, the device is available only through clinical trial participation. Go-to-market activities are primarily clinical and regulatory, supported by direct engagement with epilepsy centers (Mayo Clinic, Cook Children's Hospital), participation in the American Epilepsy Society Annual Meeting, and content/community programs including the Seizure Diaries podcast. The company has grown to more than 30 employees and contractors as of 2025.

Short descriptiontext

Cadence Neuroscience is a clinical-stage medical device company developing an implantable biomarker-targeted neuromodulation system for adults and children with drug-resistant focal epilepsy, based on technology exclusively licensed from Mayo Clinic.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedmond, United States
HQ citystring
Redmond
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromodulation therapy, epilepsy treatment, implantable medical device, brain stimulation, biomarker targeted stimulation
Industry3 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuromodulation Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Neuromodulation medical device sales
TypeHardware Sales
Description

Cadence Neuroscience is developing an implantable neuromodulation device for drug-resistant epilepsy. Upon regulatory approval, the company is expected to commercialize the device through direct sales to hospitals and epilepsy treatment centers, generating revenue from device sales and potentially associated services.

cadenceneuro.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cadence Neuroscience is developing the Cadence Neuromodulation System, an investigational implantable medical device that delivers personalized, biomarker-targeted brain stimulation for adults and children with drug-resistant focal epilepsy. The system combines proven neuromodulation hardware with proprietary software that monitors EEG biomarkers in real time and continuously adjusts stimulation parameters for each patient. The therapy is exclusively licensed from Mayo Clinic, where it has been studied in patients for over a decade.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Approximately 50% of patients treated with Cadence's biomarker targeted stimulation therapy became seizure-free, compared to approximately 6% for VNS, 8% for RNS, and 12% for DBS.
+1 more record
Product overview1 text field

Cadence Neuroscience offers a single unified product—the Cadence Neuromodulation System (also referred to as BTS or Biomarker Targeted Stimulation). This is an investigational medical device for treating drug-resistant focal epilepsy, developed in collaboration with Mayo Clinic. The system combines proven neuromodulation hardware technology with proprietary personalized software algorithms. The therapy monitors each patient's brain activity in real-time and adjusts stimulation parameters based on observed brain responses, making it a personalized treatment approach rather than a one-size-fits-all solution.

Product and service1 record
1Cadence Neuromodulation System (Biomarker Targeted Stimulation)
CategoryNeuromodulation Medical Device
Description

Investigational implantable neuromodulation device that delivers small, precise electrical pulses guided by real-time EEG biomarkers to prevent seizures in patients with drug-resistant focal epilepsy. Combines time-tested hardware materials with proprietary biomarker-targeted stimulation software licensed from Mayo Clinic. Currently accessible only through participation in a clinical trial.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Cook Children's Hospital is a key clinical collaborator for Cadence Neuroscience. The hospital, one of the busiest level 4 pediatric epilepsy centers in the nation, is engaged with Cadence for clinical studies involving pediatric epilepsy patients. Dr. Scott Perry serves as a key clinical collaborator and podcast guest, discussing neuromodulation approaches and patient care.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-01
Description

Cadence Neuroscience was incubated at Mayo Clinic and holds an exclusive license to Mayo Clinic's biomarker targeted stimulation (BTS) technology for epilepsy. Mayo Clinic researchers (including Dr. Greg Worrell and Dr. Matt Stead) developed the therapy which has been used with success in clinical trials for over 10 years. Cadence continues to collaborate closely with Mayo Clinic on ongoing clinical studies and technology development.

Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-01-01
Description

MCRA is Cadence's regulatory consulting partner, providing strategic guidance on FDA regulatory pathways (including the Humanitarian Device Exemption). MCRA's team includes former FDA staff with deep expertise in neurological devices, helping Cadence navigate the complex FDA submission and review process.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Mayo Clinic serves as Cadence's primary research and clinical development partner. Cadence's therapy is based on Mayo Clinic research and is being advanced through Mayo Clinic's ongoing clinical study, where patients undergo invasive monitoring and biomarker targeted stimulation testing. Dr. Greg Worrell (Mayo Clinic) is a key collaborator featured on Cadence's Seizure Diaries podcast.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Saluda Medical is developing closed-loop spinal cord stimulation systems with Evoked Compound Action Potential (ECAP) feedback, making it a relevant comparable for biomarker- or physiology-driven adaptive neurostim technology analogous to Cadence's BTS approach.

TypeBroad incumbent
Description

Medtronic sells Deep Brain Stimulation (DBS) systems with FDA-approved epilepsy indications, alongside a broad neuromodulation portfolio spanning Parkinson's, chronic pain, and other conditions. It represents the broadest commercial-scale neuromodulation incumbent Cadence would compete against for epilepsy share of mind.

TypeDirect peer
Description

NeuroPace developed the RNS System, a direct closed-loop neurostimulation device for drug-resistant focal epilepsy. It is the most direct commercial-stage competitor to Cadence's BTS neuromodulation system, targeting the same patient population with an EEG-responsive stimulation paradigm.

TypeDirect peer
Description

LivaNova markets the Vagus Nerve Stimulation (VNS) Therapy system, the most established neuromodulation treatment for drug-resistant epilepsy. LivaNova is also a current Cadence investor, making it both a competitor and a strategic capital partner with deep overlap in the same patient population.

TypeEmerging player
Description

Nalu Medical offers a miniaturized, externally-powered implantable neurostim system for chronic pain, providing a comparable for an emerging implantable neurostim company focused on device miniaturization and novel form factors in a specialty indication.

TypeBroad incumbent
Description

Abbott's neuromodulation business (formerly St. Jude Medical) markets DBS and spinal cord stimulation systems, with active research into closed-loop and adaptive stimulation architectures. It is a broad incumbent in the same technology category Cadence operates in.

TypeBroad incumbent
Description

Inspire Medical Systems commercializes an implantable neurostimulation device for obstructive sleep apnea, providing a relevant comparable for the regulatory, clinical-trial, and commercial path of an implantable neurostim company in a focused specialty indication.

TypeEmerging player
Description

Mainstay Medical markets an implantable restorative neurostimulation system for chronic mechanical low back pain. It is a relevant emerging-stage comparable for a clinical-to-commercial neuromodulation company navigating payer and adoption challenges in a defined specialty population.

TypeBroad incumbent
Description

Boston Scientific's Neuromodulation division offers Vercise DBS systems and is investing in next-generation directional and sensing-enabled stimulation. As a large commercial incumbent in implantable neurostim, it is a relevant comparable for Cadence's go-to-market and pipeline trajectory.

10Axonics
TypeEmerging player
Description

Axonics develops implantable sacral neuromodulation systems for incontinence and offers a successful playbook for scaling a smaller neuromodulation device company from clinical-stage to commercial-stage against large incumbents. Technology and business model overlap in the implantable stim category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cadence Neuroscience

Neuromodulation Medical Devicescadenceneuro.com

Cadence Neuroscience is a clinical-stage medical device company developing an implantable biomarker-targeted neuromodulation system for adults and children with drug-resistant focal epilepsy, based on technology exclusively licensed from Mayo Clinic.

What Cadence Neuroscience does

Cadence Neuroscience, Inc. is a privately held, clinical-stage medical device company founded in 2017 and headquartered in Redmond, Washington (incubated at Mayo Clinic in Rochester, Minnesota). The company is developing an implantable neuromodulation system called the Cadence Neuromodulation System, also referred to as Biomarker Targeted Stimulation (BTS), for the treatment of drug-resistant focal epilepsy in adults and children. The system combines established neuromodulation hardware with proprietary software that monitors real-time EEG biomarkers and adaptively adjusts stimulation parameters for each patient, distinguishing it from fixed or reactive stimulation approaches such as VNS, RNS, and DBS.

The technology was developed at Mayo Clinic over more than 10 years of clinical use and is exclusively licensed to Cadence. Early clinical data indicates that approximately 50% of patients treated with the therapy achieved seizure freedom, materially exceeding reported outcomes for existing neuromodulation alternatives (VNS ~6%, RNS ~8%, DBS ~12%). Cadence is pursuing regulatory clearance via the FDA Humanitarian Device Exemption pathway and received approval of its Investigational Device Exemption in mid-2026, with a pivotal clinical study planned later that year. The company is supported by strategic and financial partners including Mayo Clinic, Angelini Ventures, F-Prime, JAZZ Venture Partners, Lumira Ventures, Mayo Foundation, and LivaNova, with cumulative funding of approximately $41 million across a $15 million Series A (2019) and a $26 million Series B (2023).

The business model centers on hardware sales of the implantable neuromodulation device to hospitals and specialized epilepsy treatment centers following regulatory approval. Until then, the device is available only through clinical trial participation. Go-to-market activities are primarily clinical and regulatory, supported by direct engagement with epilepsy centers (Mayo Clinic, Cook Children's Hospital), participation in the American Epilepsy Society Annual Meeting, and content/community programs including the Seizure Diaries podcast. The company has grown to more than 30 employees and contractors as of 2025.

Cadence Neuroscience firmographics

Firmographics
Name
Cadence Neuroscience
Legal name
Cadence Neuroscience, Inc.
Website
https://cadenceneuro.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Cadence Neuroscience is a clinical-stage medical device company developing an implantable biomarker-targeted neuromodulation system for adults and children with drug-resistant focal epilepsy, based on technology exclusively licensed from Mayo Clinic.
Ownership category
akta.pro rank

Cadence Neuroscience industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Neuromodulation therapy
  • Epilepsy treatment
  • Implantable medical device
  • Brain stimulation
  • Biomarker targeted stimulation

Where Cadence Neuroscience is headquartered

Location

Headquarters

HQ city
Redmond
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cadence Neuroscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Neuromodulation medical device sales: Cadence Neuroscience is developing an implantable neuromodulation device for drug-resistant epilepsy. Upon regulatory approval, the company is expected to commercialize the device through direct sales to hospitals and epilepsy treatment centers, generating revenue from device sales and potentially associated services.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Cadence Neuroscience product offering

Product offering

Core offering

Cadence Neuroscience is developing the Cadence Neuromodulation System, an investigational implantable medical device that delivers personalized, biomarker-targeted brain stimulation for adults and children with drug-resistant focal epilepsy. The system combines proven neuromodulation hardware with proprietary software that monitors EEG biomarkers in real time and continuously adjusts stimulation parameters for each patient. The therapy is exclusively licensed from Mayo Clinic, where it has been studied in patients for over a decade.

Product overview

Cadence Neuroscience offers a single unified product—the Cadence Neuromodulation System (also referred to as BTS or Biomarker Targeted Stimulation). This is an investigational medical device for treating drug-resistant focal epilepsy, developed in collaboration with Mayo Clinic. The system combines proven neuromodulation hardware technology with proprietary personalized software algorithms. The therapy monitors each patient's brain activity in real-time and adjusts stimulation parameters based on observed brain responses, making it a personalized treatment approach rather than a one-size-fits-all solution.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cadence Neuromodulation System (Biomarker Targeted Stimulation) Investigational implantable neuromodulation device that delivers small, precise electrical pulses guided by real-time EEG biomarkers to prevent seizures in patients with drug-resistant focal epilepsy. Combines time-tested hardware materials with proprietary biomarker-targeted stimulation software licensed from Mayo Clinic. Currently accessible only through participation in a clinical trial.

Quantifiable outcome

  • Approximately 50% of patients treated with Cadence's biomarker targeted stimulation therapy became seizure-free, compared to approximately 6% for VNS, 8% for RNS, and 12% for DBS.
  • +1 more outcomes

Companies that use Cadence Neuroscience

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Cadence Neuroscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cadence Neuroscience partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Cook Children's Hospital (Jane and John Justin Institute for Mind Health)coreStrategic or Co-development Partner · 1 December 2025Cook Children's Hospital is a key clinical collaborator for Cadence Neuroscience. The hospital, one of the busiest level 4 pediatric epilepsy centers in the nation, is engaged with Cadence for clinical studies involving pediatric epilepsy patients. Dr. Scott Perry serves as a key clinical collaborator and podcast guest, discussing neuromodulation approaches and patient care.
  • Mayo CliniccoreStrategic or Co-development Partner · 1 May 2023Cadence Neuroscience was incubated at Mayo Clinic and holds an exclusive license to Mayo Clinic's biomarker targeted stimulation (BTS) technology for epilepsy. Mayo Clinic researchers (including Dr. Greg Worrell and Dr. Matt Stead) developed the therapy which has been used with success in clinical trials for over 10 years. Cadence continues to collaborate closely with Mayo Clinic on ongoing clinical studies and technology development.
  • MCRA (IQVIA business)majorImplementation/ SI/ Consulting Partner · 1 January 2023MCRA is Cadence's regulatory consulting partner, providing strategic guidance on FDA regulatory pathways (including the Humanitarian Device Exemption). MCRA's team includes former FDA staff with deep expertise in neurological devices, helping Cadence navigate the complex FDA submission and review process.
  • Mayo Clinic (continued)coreStrategic or Co-development Partner · 1 January 2023Mayo Clinic serves as Cadence's primary research and clinical development partner. Cadence's therapy is based on Mayo Clinic research and is being advanced through Mayo Clinic's ongoing clinical study, where patients undergo invasive monitoring and biomarker targeted stimulation testing. Dr. Greg Worrell (Mayo Clinic) is a key collaborator featured on Cadence's Seizure Diaries podcast.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Cadence Neuroscience competitors and assessment

Company assessment

Emerging players

  • Saluda Medical: Saluda Medical is developing closed-loop spinal cord stimulation systems with Evoked Compound Action Potential (ECAP) feedback, making it a relevant comparable for biomarker- or physiology-driven adaptive neurostim technology analogous to Cadence's BTS approach.
  • Nalu Medical: Nalu Medical offers a miniaturized, externally-powered implantable neurostim system for chronic pain, providing a comparable for an emerging implantable neurostim company focused on device miniaturization and novel form factors in a specialty indication.
  • Mainstay Medical: Mainstay Medical markets an implantable restorative neurostimulation system for chronic mechanical low back pain. It is a relevant emerging-stage comparable for a clinical-to-commercial neuromodulation company navigating payer and adoption challenges in a defined specialty population.
  • Axonics: Axonics develops implantable sacral neuromodulation systems for incontinence and offers a successful playbook for scaling a smaller neuromodulation device company from clinical-stage to commercial-stage against large incumbents. Technology and business model overlap in the implantable stim category.

Broad incumbents

  • Medtronic: Medtronic sells Deep Brain Stimulation (DBS) systems with FDA-approved epilepsy indications, alongside a broad neuromodulation portfolio spanning Parkinson's, chronic pain, and other conditions. It represents the broadest commercial-scale neuromodulation incumbent Cadence would compete against for epilepsy share of mind.
  • Abbott: Abbott's neuromodulation business (formerly St. Jude Medical) markets DBS and spinal cord stimulation systems, with active research into closed-loop and adaptive stimulation architectures. It is a broad incumbent in the same technology category Cadence operates in.
  • Inspire Medical Systems: Inspire Medical Systems commercializes an implantable neurostimulation device for obstructive sleep apnea, providing a relevant comparable for the regulatory, clinical-trial, and commercial path of an implantable neurostim company in a focused specialty indication.
  • Boston Scientific: Boston Scientific's Neuromodulation division offers Vercise DBS systems and is investing in next-generation directional and sensing-enabled stimulation. As a large commercial incumbent in implantable neurostim, it is a relevant comparable for Cadence's go-to-market and pipeline trajectory.

Direct peers

  • NeuroPace: NeuroPace developed the RNS System, a direct closed-loop neurostimulation device for drug-resistant focal epilepsy. It is the most direct commercial-stage competitor to Cadence's BTS neuromodulation system, targeting the same patient population with an EEG-responsive stimulation paradigm.
  • LivaNova: LivaNova markets the Vagus Nerve Stimulation (VNS) Therapy system, the most established neuromodulation treatment for drug-resistant epilepsy. LivaNova is also a current Cadence investor, making it both a competitor and a strategic capital partner with deep overlap in the same patient population.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Cadence Neuroscience social profiles

Digital presence

Cadence Neuroscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cadence Neuroscience leadership team

Management profile

Number of profiles

Profiles8 records

Cadence Neuroscience funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cadence Neuroscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cadence Neuroscience

What does Cadence Neuroscience do?

Cadence Neuroscience is developing the Cadence Neuromodulation System, an investigational implantable medical device that delivers personalized, biomarker-targeted brain stimulation for adults and children with drug-resistant focal epilepsy. The system combines proven neuromodulation hardware with proprietary software that monitors EEG biomarkers in real time and continuously adjusts stimulation parameters for each patient. The therapy is exclusively licensed from Mayo Clinic, where it has been studied in patients for over a decade.

Is Cadence Neuroscience a public or private company?

Cadence Neuroscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cadence Neuroscience founded?

Cadence Neuroscience was founded in 2017. It employs 11 to 50 people.

Where is Cadence Neuroscience based?

Cadence Neuroscience is headquartered in Redmond, United States, in the North America region.

How does Cadence Neuroscience make money?

One revenue line is on record: neuromodulation medical device sales.

Who are Cadence Neuroscience's main competitors?

Emerging players on record are Saluda Medical, Nalu Medical, Mainstay Medical and Axonics. Broad incumbents are Medtronic, Abbott, Inspire Medical Systems and Boston Scientific. Direct peers are NeuroPace and LivaNova.

Does Cadence Neuroscience have an API?

No public API is recorded for Cadence Neuroscience.

What industry is Cadence Neuroscience in?

Cadence Neuroscience's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebCadence Neuroscience Receives FDA IDE Approval to Begin Multicenter Study of its Biomarker Targeted Stimulation Therapy for Focal Drug-Resistant EpilepsyCadence Neuroscience received FDA IDE approval to begin a prospective multicenter study of its Biomarker Targeted Stimulation (BTS) therapy for focal drug-resistant epilepsy. The study will enroll 45 pediatric and adult patients at up to 10 U.S. epilepsy centers, aiming to generate evidence for a future Humanitarian Device Exemption application.PrwebCadence Neuroscience Appoints Medtech Executive Chris Cronin as CEO to Lead Clinical Execution and Platform GrowthCadence Neuroscience appointed Chris Cronin as CEO and Kent Leyde as CTO, with Cronin bringing nearly three decades of medtech leadership. The company is preparing for clinical evaluation of its Biomarker Targeted Stimulation system in focal drug-resistant epilepsy, its first indication.PrwebCadence Neuroscience Announces Medical Device Veteran Daniel Moore as Independent Board DirectorCadence Neuroscience announced Daniel Moore as an independent board director. Moore has extensive experience in the medical device industry, particularly in epilepsy treatment and neuromodulation technologies.BeBeezAngelini Ventures investe 6 mln $ nella start up Usa Cadence Neuroscience (trattamenti per l’epilessia)Angelini Ventures has invested 6 million dollars in the American startup Cadence Neuroscience, which is developing a continuous neurostimulation system for treating drug-resistant epilepsy, in partnership with the Mayo Clinic. This investment is part of a larger Series B funding round totaling 26 million dollars aimed at completing preliminary clinical studies and obtaining FDA approval. The technology developed by Cadence Neuroscience could significantly advance treatment for epilepsy and other brain disorders.Startup BusinessAngelini Ventures investe in Cadence NeuroscienceAngelini Ventures invested $6 million in US-based Cadence Neuroscience as part of a $26 million Series B funding round. The capital will support clinical studies and FDA approval efforts for the company's neuro-modulation technology designed to treat drug-resistant epilepsy. New investors including F-Prime Capital and LivaNova PLC joined the round, with representatives from Lumira Ventures and F-Prime Capital joining Cadence's board.FinSMEsCadence Neuroscience Raises $26M in Series B FinancingCadence Neuroscience raised $26M in Series B funding led by Angelini Lumira Biosciences Fund, with participation from F-Prime Capital, LivaNova USA, and others. The company will use the funds to complete pivotal clinical studies and pursue FDA clearance for its neuromodulation therapy for epilepsy.PR NewswireCadence Neuroscience Secures $26 Million in Series B Financing for Clinical Trials of Epilepsy Neuromodulation TherapyCadence Neuroscience secured $26 million in Series B financing led by Angelini Lumira Biosciences Fund to support pivotal clinical studies and pursue FDA clearance for its epilepsy neuromodulation therapy. The investment round included new investors such as F-Prime Capital, LivaNova USA, and Mayo Clinic, alongside existing backer JAZZ Venture Partners. These funds will enable the company to complete clinical evaluations of its chronic subthreshold cortical stimulation technology.PR NewswireCadence Neuroscience Secures $26 Million in Series B Financing for Clinical Trials of Epilepsy Neuromodulation TherapyCadence Neuroscience secured $26 million in Series B financing led by Angelini Lumira Biosciences Fund, with participation from investors including F-Prime Capital, LivaNova USA, and Mayo Clinic. The company plans to utilize these funds to complete pivotal clinical studies for its neuromodulation therapy aimed at treating drug-resistant epilepsy and pursue FDA clearance.